Intimation of Receipt of No-objection from BSE Limited (BSE) for reclassification from "Promoter/ Promoter Group" Category to "Public" Category shareholder of the Company pursuant to Regulation ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Oxygenta Pharmaceutical Ltd has received BSE's no-objection to reclassify four members of its promoter/promoter group — Sai Sudhakar Vankineni, Snigdha Vankineni, Sumanth Simha Vankineni, and Jhansi Rani Vankineni — from the 'Promoter/Promoter Group' category to the 'Public' category shareholder status under Regulation 31A of SEBI LODR Regulations. The reclassification application was originally made on August 29, 2025, and BSE cleared it via its letter dated October 16, 2025. The company will now seek shareholder approval at an upcoming shareholders' meeting to complete the reclassification process. Post-approval, these four individuals will be treated as public shareholders of the company even though they continue to hold the same shares.
This is a governance and disclosure event that reclassifies the above four persons as public shareholders rather than promoters, without any actual change in share ownership. The shares held by them remain the same, but their status changes. Impact on share price or promoter shareholding depends on combined shareholding of these individuals, which is not disclosed here; shareholder approval at an EGM is still required to complete the change.